Ireland
--:--IST
Priya Life Science Compound trial record
Compound · clinical trials

RBD1119 clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 2 trials in our Sweden and Australia registers that name RBD1119 as an intervention. Synced 21 Oct 2026
2Current trials
0Recruiting now
2Lead sponsors
2Country registers
At a glance

RBD1119 is named as an intervention in 2 current clinical trials in our Sweden and Australia registers. None are recruiting at the moment. The most common phase is Phase 2. The sponsor with the most trials is Ribocure Pharmaceuticals AB (1). The most-studied condition is Stable Coronary Artery Disease.

Patient leaflets for RBD1119

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Not yet open150%
  • Active, closed150%

Trials by phase

  • Phase 2150%
  • Phase 1150%
01

Clinical trials of RBD1119

2 trials
StudyPhaseStatusLead sponsorRegisters
RBD1119 in Coronary Artery Disease (CAD)
NCT07884136 · ClinicalTrials.gov ↗ · Stable Coronary Artery Disease
Phase 2 Not yet open Ribocure Pharmaceuticals AB Sweden
Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy Participants
NCT07042594 · ClinicalTrials.gov ↗ · Healthy Volunteers
Phase 1 Active, closed Suzhou Ribo Life Science Co. Ltd Australia

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with RBD1119

2 conditions
Stable Coronary Artery Disease1Healthy Volunteers1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Ribocure Pharmaceuticals AB1
Suzhou Ribo Life Science Co. Ltd1
04

By country register

RegisterTrialsRecruiting
Clinical trials in Sweden10
Clinical trials in Australia10

A trial with sites in more than one country appears in each of those registers.

05

Related compounds

06

Questions about RBD1119 trials

How many clinical trials are testing RBD1119?

2 current trials in our Sweden and Australia registers name RBD1119 as a drug or biological intervention, as of the registry sync on 21 October 2026. Completed and withdrawn studies are not counted.

Are RBD1119 trials recruiting patients?

Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.

Who sponsors RBD1119 clinical trials?

Ribocure Pharmaceuticals AB (1) and Suzhou Ribo Life Science Co. Ltd (1). The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how RBD1119 works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how RBD1119 works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists RBD1119 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 21 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.